Hims Obesity Drug Business May Get Boost as Employers Cut Coverage

GOOGL shares have declined by more than 6% in the last 24 hours, closing at $345.36. Although the RSI at 37.3 is approaching oversold territory, the MACD remains in negative territory and below the signal line. Trading below the 20-day simple moving average ($347.41) and the 50-day simple moving average ($359.49) indicates short-term weakness. While the news headline does not directly concern Google, the selling pressure on technology stocks in general and the deterioration in technical indicators suggest that the downtrend may continue over the next 1-3 days.

The news headline suggests that employers scaling back obesity drug coverage could be a potential support for HIMS, though it does not yet indicate a clear increase in demand. Technical indicators present mixed signals: the RSI at 46.7 is in neutral territory, while the MACD is below the signal line and negative, pointing to short-term weakness. The price closed below the 20-day SMA (33.40) and experienced a 7% decline in the last 24 hours, indicating continued selling pressure. However, the 50-day SMA (32.53) could provide nearby support. With the positive potential of the news balanced by technical weakness, short-term direction remains uncertain.